AVE — Avecho Biotechnology Income Statement
0.000.00%
Last trade - 00:00- AU$34.90m
- AU$30.25m
- AU$1.24m
Annual income statement for Avecho Biotechnology, fiscal year end - December 31st, AUD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.794 | 1.13 | 0.474 | 1.13 | 1.24 |
| Cost of Revenue | |||||
| Gross Profit | 0.508 | 0.793 | -0.044 | 0.672 | 0.888 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 4.21 | 3.47 | 3.91 | 4.25 | 5.65 |
| Operating Profit | -3.42 | -2.34 | -3.44 | -3.12 | -4.42 |
| Net Income Before Taxes | -3.42 | -2.34 | -3.44 | -3.12 | -4.42 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -3.42 | -2.34 | -3.44 | -3.12 | -4.42 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -3.42 | -2.34 | -3.44 | -3.12 | -4.42 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -3.42 | -2.34 | -3.44 | -3.12 | -4.42 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.002 | -0.001 | -0.002 | -0.001 | -0.001 |